{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:25:04Z","timestamp":1793121904143,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017709","name":"Hunan Department of Transportation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017709","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019170","name":"Hunan City University Key Laboratory of Key Technologies of Digital Urban-Rural Spatial Planning of Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017695","name":"Health Commission of Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017695","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejmech.2024.116838","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T12:52:57Z","timestamp":1725627177000},"page":"116838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"special_numbering":"C","title":["Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity"],"prefix":"10.1016","volume":"279","author":[{"given":"Weijiang","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengsong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6887-9184","authenticated-orcid":false,"given":"Junmei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejmech.2024.116838_bib1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2174\/1871523017666180126150901","article-title":"Therapeutic potential of N-heterocyclic analogs as anti-inflammatory agents","volume":"16","author":"Dhingra","year":"2017","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"10.1016\/j.ejmech.2024.116838_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111804","article-title":"Structure-activity relationships (SAR) of triazine derivatives: promising antimicrobial agents","volume":"185","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2024.116838_bib3","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.2174\/1871520620666200705214917","article-title":"Nitrogen-containing heterocycles as anticancer agents: an overview","volume":"20","author":"Lang","year":"2020","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116838_bib4","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1021\/acs.jafc.0c05558","article-title":"Highly efficient synthesis and Acaricidal and insecticidal activities of novel oxazolines with N-heterocyclic substituents","volume":"69","author":"Chen","year":"2021","journal-title":"J. Agric. Food Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116838_bib5","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1002\/ps.5743","article-title":"Spiro N-methoxy piperidine ring containing aryldiones for the control of sucking insects and mites: discovery of spiropidion","volume":"76","author":"Muehlebach","year":"2020","journal-title":"Pest Manag. Sci."},{"key":"10.1016\/j.ejmech.2024.116838_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/bs.ampbs.2020.01.004","article-title":"Bacterial catabolism of s-triazine herbicides: biochemistry, evolution and application","volume":"76","author":"Esquirol","year":"2020","journal-title":"Adv. Microb. Physiol."},{"issue":"24","key":"10.1016\/j.ejmech.2024.116838_bib7","doi-asserted-by":"crossref","first-page":"10257","DOI":"10.1021\/jm501100b","article-title":"Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals","volume":"57","author":"Vitaku","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116838_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejmech.2016.09.023","article-title":"Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities","volume":"125","author":"Akhtar","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116838_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106680","article-title":"Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: biological activity and structural activity relationship","volume":"138","author":"Taruneshwar Jha","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116838_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/1570163814666170915134018","article-title":"A retrospect study on thiazole derivatives as the potential antidiabetic agents in drug discovery and developments","volume":"15","author":"Khatik","year":"2018","journal-title":"Curr. Drug Discov. Technol."},{"issue":"15","key":"10.1016\/j.ejmech.2024.116838_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115585","article-title":"Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants","volume":"28","author":"Grover","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116838_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113165","article-title":"Discovery of natural anti-inflammatory alkaloids: potential leads for the drug discovery for the treatment of inflammation","volume":"213","author":"Bai","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116838_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4155\/fmc-2019-0063","article-title":"Bis-(imidazole\/benzimidazole)-pyridine derivatives: synthesis, structure and antimycobacterial activity","volume":"12","author":"Antoci","year":"2020","journal-title":"Future Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116838_bib14","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/14786419.2018.1548456","article-title":"Synthesis of nitrogen-containing monoterpenoids with antibacterial activity","volume":"34","author":"Kozio\u0142","year":"2020","journal-title":"Nat. Prod. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116838_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14479","article-title":"Nitrogen-containing heterocyclic compounds: a ray of hope in depression?","volume":"103","author":"Choudhary","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116838_bib16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/10781552231216886","article-title":"Pirtobrutinib: a novel non-covalent BTK inhibitor for the treatment of adults with relapsed\/refractory mantle cell lymphoma","volume":"30","author":"Davis","year":"2024","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"Supplement_1","key":"10.1016\/j.ejmech.2024.116838_bib17","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood-2019-124362","article-title":"LOXO-305: targeting C481S Bruton tyrosine kinase in patients with ibrutinib-resistant CLL","volume":"134","author":"Brown","year":"2019","journal-title":"Blood"},{"issue":"10277","key":"10.1016\/j.ejmech.2024.116838_bib18","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116838_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40265-023-01860-1","article-title":"Pirtobrutinib: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116838_bib20","series-title":"TW202225146 A1","author":"Arguelles","year":"2022"},{"key":"10.1016\/j.ejmech.2024.116838_bib21","series-title":"CN116655538 A1","author":"Cheng","year":"2023"},{"key":"10.1016\/j.ejmech.2024.116838_bib22","first-page":"1","article-title":"Sparsentan: a first-in-class dual endothelin and angiotensin II receptor antagonist","author":"Chiu","year":"2023","journal-title":"Ann. Pharmacother."},{"issue":"26","key":"10.1016\/j.ejmech.2024.116838_bib23","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1021\/jm970872k","volume":"41","author":"Murugesan","year":"1998","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116838_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1021\/jm049548x","article-title":"Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics","volume":"48","author":"Murugesan","year":"2005","journal-title":"J. Med. Chem."},{"issue":"10417","key":"10.1016\/j.ejmech.2024.116838_bib25","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116838_bib26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40265-023-01864-x","article-title":"Sparsentan: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116838_bib27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/MS9.0000000000001620","article-title":"Novel FDA-approved zavegepant drug for treating migraine","volume":"86","author":"Ahmed","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"issue":"11","key":"10.1016\/j.ejmech.2024.116838_bib28","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1016\/j.bmcl.2013.04.012","volume":"23","author":"Chaturvedula","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"16","key":"10.1016\/j.ejmech.2024.116838_bib29","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1021\/jm800546t","volume":"51","author":"Degnan","year":"2008","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116838_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","article-title":"Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial","volume":"22","author":"Lipton","year":"2023","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116838_bib31","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-023-01885-6","article-title":"Zavegepant: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"issue":"14","key":"10.1016\/j.ejmech.2024.116838_bib32","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1016\/j.bmcl.2012.05.074","article-title":"The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1","volume":"22","author":"Han","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116838_bib33","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1021\/jo900368k","article-title":"Catalytic asymmetric syntheses of alpha-amino and alpha-hydroxyl acid derivatives","volume":"74","author":"Han","year":"2009","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2024.116838_bib34","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.2147\/NDT.S371483","article-title":"Rett syndrome and MECP2 duplication syndrome: disorders of MeCP2 dosage","volume":"18","author":"Collins","year":"2022","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116838_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2020-000717","article-title":"Consensus guidelines on managing Rett syndrome across the lifespan","volume":"4","author":"Fu","year":"2020","journal-title":"BMJ Paediatr Open"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116838_bib36","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.170216","article-title":"Rett syndrome: a neurological disorder with metabolic components","volume":"8","author":"Kyle","year":"2018","journal-title":"Open Biol"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116838_bib37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/neu.2008.0629","article-title":"NNZ-2566, a glypromate analog, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury","volume":"26","author":"Lu","year":"2009","journal-title":"J. Neurotrauma"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116838_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/138955712798868995","article-title":"GPE and GPE analogues as promising neuroprotective agents","volume":"12","author":"Cacciatore","year":"2012","journal-title":"Mini Rev. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2024.116838_bib39","first-page":"e1912","article-title":"Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome","volume":"92","author":"Glaze","year":"2019","journal-title":"Neurol. Now."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116838_bib40","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40261-022-01156-4","article-title":"A phase 1, open-label study to evaluate the effects of food and evening dosing on the pharmacokinetics of oral trofinetide in healthy adult subjects","volume":"42","author":"Darwish","year":"2022","journal-title":"Clin. Drug Invest."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116838_bib41","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study","volume":"29","author":"Neul","year":"2023","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116838_bib42","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40265-023-01883-8","article-title":"Trofinetide: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116838_bib43","series-title":"CN114667136 A","author":"Brewer M P","year":"2022"},{"issue":"21","key":"10.1016\/j.ejmech.2024.116838_bib44","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \"activated PI3K\u03b4 syndrome\"-targeted therapy with the PI3K\u03b4 inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ejmech.2024.116838_bib45","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1021\/acsmedchemlett.7b00293","article-title":"Discovery of CDZ173 (leniolisib), representing a structurally novel class of PI3K delta-selective inhibitors","volume":"8","author":"Hoegenauer","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116838_bib46","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/bdd.2157","article-title":"CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib","volume":"39","author":"De Buck","year":"2018","journal-title":"Biopharm Drug Dispos."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116838_bib47","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2022018546","article-title":"A randomized, placebo-controlled phase 3 trial of the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome","volume":"141","author":"Rao","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116838_bib48","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40265-023-01895-4","article-title":"Leniolisib: first approval","volume":"83","author":"Duggan","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116838_bib49","series-title":"CN102971317 A1","author":"Cooke","year":"2013"},{"key":"10.1016\/j.ejmech.2024.116838_bib50","series-title":"CN117534672 A1","author":"Cheng","year":"2024"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116838_bib51","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/humupd\/dmu009","article-title":"The kisspeptin-GnRH pathway in human reproductive health and disease","volume":"20","author":"Skorupskaite","year":"2014","journal-title":"Hum. Reprod. Update"},{"issue":"7","key":"10.1016\/j.ejmech.2024.116838_bib52","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1021\/acsmedchemlett.5b00117","article-title":"Optimization of novel antagonists to the neurokinin-3 receptor for the treatment of sex-hormone disorders (Part II)","volume":"6","author":"Hoveyda","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116838_bib53","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/13543784.2021.1893305","article-title":"Fezolinetant in the treatment of vasomotor symptoms associated with menopause","volume":"30","author":"Depypere","year":"2021","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116838_bib54","first-page":"737","article-title":"Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial","volume":"141","author":"Neal-Perry","year":"2023","journal-title":"Obstet. Gynecol."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116838_bib55","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s40265-023-01917-1","article-title":"Fezolinetant: first approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116838_bib56","series-title":"WO2014154895 A1","author":"Hoveyda","year":"2014"},{"issue":"12","key":"10.1016\/j.ejmech.2024.116838_bib57","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/13543784.2021.2012149","article-title":"Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata","volume":"30","author":"Eisman","year":"2021","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116838_bib58","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116838_bib59","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116838_bib60","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s40262-023-01318-3","article-title":"Evolution of ritlecitinib population pharmacokinetic models during clinical drug development","volume":"62","author":"Wojciechowski","year":"2023","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116838_bib61","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1021\/acs.oprd.9b00198","article-title":"Process development and scale up of a selective JAK3 covalent inhibitor PF-06651600","volume":"23","author":"Tao","year":"2019","journal-title":"Org. Process Res. Dev."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116838_bib62","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/bcp.15695","article-title":"Evaluation of the effect of ritlecitinib on the pharmacokinetics of caffeine in healthy participants","volume":"89","author":"Liu","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116838_bib63","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","article-title":"Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program","volume":"25","author":"King","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"issue":"14","key":"10.1016\/j.ejmech.2024.116838_bib64","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","article-title":"Ritlecitinib: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.ejmech.2024.116838_bib65","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1080\/14656566.2020.1801637","article-title":"Quizartinib for the treatment of acute myeloid leukemia","volume":"21","author":"Garcia-Horton","year":"2020","journal-title":"Expet Opin. Pharmacother."},{"issue":"9550","key":"10.1016\/j.ejmech.2024.116838_bib66","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ejmech.2024.116838_bib67","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/jm9007533","article-title":"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor","volume":"52","author":"Chao","year":"2009","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2024.116838_bib68","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116838_bib69","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7150\/thno.46593","article-title":"LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia","volume":"11","author":"Yu","year":"2021","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116838_bib70","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s12185-019-02709-8","article-title":"Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study","volume":"110","author":"Usuki","year":"2019","journal-title":"Int. J. Hematol."},{"issue":"10388","key":"10.1016\/j.ejmech.2024.116838_bib71","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.116838_bib72","first-page":"529","article-title":"AML and FLT3: an update on FDA-approved or under review kinase inhibitors targeting FLT3 kinase","volume":"67","author":"Alaa El-Deen","year":"2023","journal-title":"Egypt. J. Chem."},{"key":"10.1016\/j.ejmech.2024.116838_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator","volume":"181","author":"Althaus","year":"2020","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.ejmech.2024.116838_bib74","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","article-title":"An emerging circuit pharmacology of GABA(A) receptors","volume":"39","author":"Engin","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"issue":"18","key":"10.1016\/j.ejmech.2024.116838_bib75","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1021\/acs.jmedchem.7b00846","article-title":"Neuroactive steroids. 2. 3\u03b1-Hydroxy-3\u03b2-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5\u03b2-pregnan-20-one (SAGE-217): a clinical next generation neuroactive steroid positive allosteric modulator of the (\u03b3-Aminobutyric acid)(A) receptor","volume":"60","author":"Martinez Botella","year":"2017","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116838_bib76","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41386-023-01751-9","article-title":"Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study","volume":"49","author":"Parikh","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.ejmech.2024.116838_bib77","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1176\/appi.ajp.20220785","article-title":"Zuranolone for the treatment of postpartum depression","volume":"180","author":"Deligiannidis","year":"2023","journal-title":"Am. J. Psychiatr."},{"issue":"16","key":"10.1016\/j.ejmech.2024.116838_bib78","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-023-01953-x","article-title":"Zuranolone: first approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116838_bib79","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3389\/fendo.2019.00908","article-title":"Fibrodysplasia ossificans progressiva (FOP): a segmental progeroid syndrome","volume":"10","author":"Pignolo","year":"2019","journal-title":"Front. Endocrinol."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116838_bib80","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/bcp.13823","article-title":"Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva","volume":"85","author":"Wentworth","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116838_bib81","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40272-019-00330-0","article-title":"Current and emerging therapeutic options for the management of rare skeletal diseases","volume":"21","author":"Semler","year":"2019","journal-title":"Paediatr Drugs"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116838_bib82","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40265-022-01709-z","article-title":"Palovarotene: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116838_bib83","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/jbmr.4655","article-title":"Palovarotene for fibrodysplasia ossificans progressiva (FOP): results of a randomized, placebo-controlled, double-blind phase 2 trial","volume":"37","author":"Pignolo","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejmech.2024.116838_bib84","series-title":"WO0228810 A2","author":"Lapierre","year":"2002"},{"issue":"11","key":"10.1016\/j.ejmech.2024.116838_bib85","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.3324\/haematol.2022.282612","article-title":"Momelotinib (JAK1\/JAK2\/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis","volume":"108","author":"Tefferi","year":"2023","journal-title":"Haematologica"},{"issue":"10373","key":"10.1016\/j.ejmech.2024.116838_bib86","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(23)00171-X","article-title":"Gaining MOMENTUM against anaemic myelofibrosis","volume":"401","author":"Ikeda","year":"2023","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ejmech.2024.116838_bib87","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ejmech.2024.116838_bib88","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1016\/j.bmcl.2009.08.071","article-title":"Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)","volume":"19","author":"Burns","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116838_bib89","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1124\/dmd.117.078899","article-title":"Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development","volume":"46","author":"Zheng","year":"2018","journal-title":"Drug Metab. Dispos."},{"issue":"10373","key":"10.1016\/j.ejmech.2024.116838_bib90","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ejmech.2024.116838_bib91","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s40265-023-01964-8","article-title":"Momelotinib: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"22","key":"10.1016\/j.ejmech.2024.116838_bib92","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116838_bib93","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.eururo.2022.05.019","article-title":"Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical trial","volume":"82","author":"Crabb","year":"2022","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116838_bib94","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1021\/jm901788j","article-title":"Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)","volume":"53","author":"Mchardy","year":"2010","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116838_bib95","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1021\/jm301762v","article-title":"Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases","volume":"56","author":"Addie","year":"2013","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116838_bib96","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1111\/bcp.15831","article-title":"The effect of food and acid-reducing agents on the pharmacokinetic profile of capivasertib: results from a randomized, crossover study","volume":"89","author":"Miller","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116838_bib97","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40265-024-01998-6","article-title":"Capivasertib: first approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116838_bib98","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa2210140","article-title":"Nirogacestat, a \u03b3-secretase inhibitor for desmoid tumors","volume":"388","author":"Gounder","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116838_bib99","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.bmcl.2010.12.117","article-title":"Diamide amino-imidazoles: a novel series of \u03b3-secretase inhibitors for the treatment of Alzheimer's disease","volume":"21","author":"Brodney","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116838_bib100","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1016\/j.bmcl.2010.12.118","article-title":"Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as \u03b3-secretase inhibitors: discovery of PF-3084014","volume":"21","author":"Brodney","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116838_bib101","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-024-02002-x","article-title":"Nirogacestat: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"}],"updated-by":[{"DOI":"10.1016\/j.ejmech.2024.117087","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000}}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424007190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424007190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T11:40:12Z","timestamp":1734003612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424007190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":101,"alternative-id":["S0223523424007190"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116838","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejmech.2024.117087","asserted-by":"object"}]},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116838"}}